Question · asked by 1 review
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or: Chronic lung disease
- Population
- treatment of apnea
- Intervention
- Doxapram
- Comparison
- no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or
- Outcome
- Chronic lung disease
The review found no eligible studies for this question.
What each review found
Current versions onlyNo studies found 3 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3a. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram compared to no treatment for the treatment of apnea · treatment of apnea The review found no eligible studies for this question. Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3b. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea The review found no eligible studies for this question. Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3c. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea The review found no eligible studies for this question. Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Doxapram for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.